Drug vignettes: Tocilizumab, CEBM (Updated 26th October 2020)

Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are 2 External 0 0 0 reported false https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf true false%> to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19.

Source: Current Awareness Service for Health (CASH) - October 28, 2020 Category: Consumer Health News Source Type: news